T2 Biosystems Appoints Laura Adams to Its Board of Directors
T2 Biosystems (NASDAQ:TTOO) has appointed Laura Adams to its Board of Directors, effective immediately. With over 20 years in healthcare, Adams is noted for her leadership in digital health transformation. Previously, she was the founding President and CEO of the Rhode Island Quality Institute, where she achieved significant reductions in infections and sepsis mortality. Adams' expertise will be invaluable as T2 Biosystems aims to enhance its culture-independent diagnostics, addressing critical healthcare needs, particularly in sepsis management.
- Laura Adams brings 20 years of experience in healthcare innovation, enhancing T2 Biosystems' leadership.
- Adams' previous successes in reducing catheter-related infections and sepsis mortality can inform T2's growth strategies.
- Concerns may arise regarding continuity and integration of Adams into the existing board dynamics.
LEXINGTON, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately.
“We are excited to have Laura join the T2 Biosystems Board of Directors,” said John Sperzel, Chairman and CEO at T2 Biosystems. “Her success as a healthcare delivery innovator has deep roots in understanding the critical threats posed by infections and sepsis. She will be a crucial asset to T2 Biosystems as we continue on our growth trajectory.”
Ms. Adams currently serves as Special Advisor at the National Academy of Medicine (NAM), providing leadership for the NAM Digital Health and Evidence Mobilization portfolios. Her primary expertise is digital health transformation, healthcare innovation, and human-centered care and for the past 20 years has held leadership positions across a wide variety of healthcare focused organizations and as a founding member of multiple healthcare IT companies.
Of note, from 2001 to 2019, Ms. Adams served as the the founding President and CEO of the Rhode Island Quality Institute (RIQI), an organization enabling the best healthcare for the state by providing and connecting trusted data. As part of her tenure she led the Rhode Island Statewide ICU Collaborative as Principal Investigator driving a
Previously, Ms. Adams also chaired the Institute of Medicine’s (IOM) Planning Committee for the “Digital Infrastructure for Population Health and a Learning Healthcare System” initiative. Ms. Adams was Founder, President and CEO of Decision Support Systems, a New York-based company specializing in Internet-based healthcare decision support. Laura Adams has been a long-time faculty member of the Institute for Healthcare Improvement (IHI) in Boston. She serves on the board of Translational Medicine Accelerator (TMA), a Boston-based precision medicine company focusing on patients with recalcitrant and rare diseases; and the Oversight Council for the MA Center for Health Information and Analysis. Ms. Adams earned a Master of Science from the University of Colorado Health Sciences Center, and a B.S. from the University of Northern Colorado, of which she was named Distinguished Alumnus in 2010.
“I am thrilled to join the T2 Biosystems Board of Directors and to assist this team driving innovation focused on a crucial unmet need in healthcare,” said Laura Adams. “Over my career I have addressed the unacceptable risks and costs for patients and the healthcare system caused by reliance on blood culture diagnostics to administer targeted therapy for patients suspected of sepsis. I believe T2’s transformative culture-independent diagnostics can improve the standard of care for patients at risk of sepsis.”
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the ability of T2’s transformative culture-independent diagnostics to improve the standard of care for patients at risk of sepsis, as well as statements that include the words “expect,” “intend,” “plan”, “believe”, “project”, “forecast”, “estimate,” “may,” “should,” “anticipate,” and similar statements of a future or forward looking nature. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, (i) any inability to (a) realize anticipated benefits from commitments, contracts or products; (b) successfully execute strategic priorities; (c) bring products to market; (d) expand product usage or adoption; (e) obtain customer testimonials; (f) accurately predict growth assumptions; (g) realize anticipated revenues; (h) incur expected levels of operating expenses; or (i) increase the number of high-risk patients at customer facilities; (ii) failure of early data to predict eventual outcomes; (iii) failure to make or obtain anticipated FDA filings or clearances within expected time frames or at all; or (iv) the factors discussed under Item 1A. "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission, or SEC, on March 16, 2020, and other filings the Company makes with the SEC from time to time. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, unless required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. Thus, no one should assume that the Company’s silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Media Contact:
Meagan Dominick, Vault Communications
mdominick@vaultcommunications.com
773-369-4255
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
What is the significance of Laura Adams joining T2 Biosystems Board of Directors?
How does Laura Adams' experience relate to T2 Biosystems' mission?
What has Laura Adams accomplished in her previous roles?
How might Laura Adams impact T2 Biosystems' future?
